Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Status:
Terminated
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or
everolimus works in treating patients with kidney cancer that does not respond to treatment.
Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Everolimus may also stop the growth of kidney cancer by
blocking blood flow to the tumor. It is not yet known whether Akt inhibitor MK2206 or
everolimus is more effective in treating kidney cancer.